Lungs News and Research

RSS

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Aeolus Pharmaceuticals, Inc. today announced that it has been awarded a total of approximately $489,000 under the Qualifying Therapeutic Discovery Grant Program (QDTP) administered by the Internal Revenue Service and the Department of Health and Human Services.

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

ADVENTRX submits NDA for Exelbine to FDA

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.

3 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Study finds risk of toxicity in Phase I radiation oncology clinical trials

Risks to patients enrolled in Phase I radiation oncology clinical trials are higher than previously appreciated, according to a study conducted by researchers from the Kimmel Cancer Center at Jefferson. The findings will be presented at the American Society of Radiation Oncology (ASTRO) annual meeting in San Diego.

3 Nov 2010

Synergenz awarded $94,836 research grant under federal QTDP program

Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

UIC awarded $12M to study acquired and familial causes of heart failure

Researchers at the University of Illinois at Chicago have been awarded more than $12 million by the National Heart, Lung, and Blood Institute to investigate both the acquired and familial causes of heart failure -- with the aim of identifying markers for diagnosis and targets for cures.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

NIH awards Nemours/Alfred I. duPont Hospital for Children additional $9.5M research grant

The Center for Pediatric Research (CPR) at the Nemours/Alfred I. duPont Hospital for Children was recently awarded an additional 5-year, $9.5-million Center for Biomedical Research Excellence (COBRE) grant from the National Institutes of Health (NIH), National Center for Research Resources (NCRR). This competitive award will allow Nemours to continue to expand the CPR and support the recruitment of additional faculty to this diverse pediatric clinical and research facility.

3 Nov 2010

South Dakota passes strong smoke-free law

The people of South Dakota delivered a historic victory for health and the right to breathe clean air by overwhelmingly approving Referred Question 12 that makes almost all workplaces, including restaurants, bars and gaming facilities, smoke-free. With bipartisan support, South Dakota is the 29th state to pass a strong smoke-free law that includes all restaurants and bars.

3 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

Novel technology using quantum dots increases drug uptake in lung injury

Researchers at the University at Buffalo have developed a novel technology using quantum dots that is expected to have major implications for research and treatment of tuberculosis, as well as other inflammatory lung diseases.

2 Nov 2010

LCA releases 2010 National Report Card on Lung Cancer

Today, Lung Cancer Alliance (LCA) released its Annual National Report Card on Lung Cancer, an overall assessment of the nation's response to the continuing high mortality of lung cancer, the leading cancer killer.

2 Nov 2010

X-BODY receives research grant for therapeutic project against metastatic tumor stem cells

X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.

2 Nov 2010

Study finds invasive patterns of lung cancer in pediatric patients

Because primary lung adenocarcinoma is exceedingly rare in the pediatric population, it is difficult to properly classify certain lung tumors in children and adolescents. While anecdotal reports of pediatric patients with lung cancer lesions exist, little research has been conducted to link the disease in children to similar pulmonary malignancies in adults.

2 Nov 2010

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced it will showcase Dynamic Edge™ Gating Technology, recently cleared by the U.S. Food and Drug Administration, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), now underway at the San Diego Convention Center.

1 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010